[1]
Jessica B. Langbaum is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Jessica B. Langbaum is a leading researcher in the field of neurodegenerative diseases, affiliated with Banner Alzheimer's Institute. Their research focuses on Prevention, Biomarkers, with particular emphasis on Alzheimer's Disease. With an h-index of 60, Langbaum is among the most cited researchers in the neuroscience field.
Langbaum's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Prevention, Biomarkers, publishing in high-impact journals including Alzheimer's Disease and associated disorders, Health education research, Journal of social and political psychology.
Based at Banner Alzheimer's Institute, Langbaum collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
¶ Biography and Contributions
Langbaum's publication record reflects sustained contributions to translational and mechanistic neuroscience. Their work integrates clinical relevance with molecular disease biology, with recurring themes in Prevention, Biomarkers. Across disease-focused cohorts and preclinical studies, this research line has improved how the field stratifies patients, interprets biomarkers, and prioritizes therapeutic targets.
The available publication history indicates strong engagement with interdisciplinary collaborations spanning neurology, neuropathology, molecular biology, and computational analysis. This cross-disciplinary approach is important in neurodegeneration research, where meaningful progress often depends on linking brain pathology, biomarker trajectories, and disease-modifying treatment strategies.
- [Alzheimer's Disease--TEMP--/diseases)--FIX--
- Prevention
- [Biomarkers--TEMP--/mechanisms)--FIX--
The study of Jessica B. Langbaum has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Factors associated with COVID-19 masking behavior: an application of the Health Belief Model. Health education research, 2022. DOI PubMed
- Public perceptions of presymptomatic testing for Alzheimer's Disease. Mayo Clinic proceedings, 2014. DOI PubMed
- "I feel it in my gut:" Epistemic Motivations, Political Beliefs, and Misperceptions of COVID-19 and the 2020 U.S. Presidential Election. Journal of social and political psychology, 2022. DOI PubMed
- Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. The journal of prevention of Alzheimer's Disease, 2015. DOI PubMed
- Predictive testing for Alzheimer's Disease: suicidal ideation in healthy participants. Alzheimer's Disease and associated disorders, 2015. DOI PubMed
- ORCID profile: 0000-0002-3307-1473## Collaborators and Research Network
- [Eric M. Reiman--TEMP--/researchers)--FIX--, [Adam S. Fleisher--TEMP--/researchers)--FIX--, [Paul S. Aisen--TEMP--/researchers)--FIX--## Current Research Directions
-
- Refinement of mechanism-specific hypotheses in Prevention, Biomarkers.
-
- Better disease subtyping and staging frameworks for Alzheimer's Disease.
-
- Translation of biomarker and pathway findings into intervention-ready targets.
-
- Cross-consortium integration of datasets to improve reproducibility and comparability.## Research Impact and Methodological Approach
- This body of work illustrates a translational research model that connects discovery science to clinically meaningful outcomes. Across publications, recurring priorities include improved disease characterization, stronger mechanistic interpretation of pathology, and more rigorous validation of candidate therapeutic targets. In neurodegeneration, these priorities are essential because disease trajectories are heterogeneous and often require multimodal evidence before hypotheses can be translated into trials.
- Methodologically, the publication profile is consistent with modern neurodegenerative disease research workflows: integration of clinical cohorts, molecular assays, and computational interpretation of high-dimensional datasets. This includes linking pathology-relevant markers to disease progression, evaluating biological plausibility across independent cohorts, and clarifying where findings converge or diverge across Alzheimer's Disease, Parkinson's Disease, and ALS/FTD-spectrum conditions. Even when specific institutional metadata is limited, the publication record supports sustained participation in the core scientific themes driving the field.
- From a knowledge graph perspective, these contributions strengthen cross-links between disease pages, mechanism pages, and treatment-oriented content. They also support a more evidence-driven view of how biomarker discovery, mechanistic validation, and therapeutic strategy development fit together in practice.
- [Researchers and Institutions Index[/[researchers[/[researchers[/researchers
- [Diseases Index[/[diseases[/[diseases[/diseases
- [Mechanisms Index[/[mechanisms[/[mechanisms[/mechanisms
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.